Program: Oral and Poster Abstracts
Session: 623. Lymphoma: Chemotherapy, excluding Pre-Clinical Models: Poster III
Patients and Methods: We analyzed virological and hematological response of 26 patients (pts) with indolent B-cell non-Hodgkin lymphomas (NHL) or chronic lymphocytic leukemia (CLL) and HCV infection treated with an IFN-free AT. We included the 5 cases reported in literature (Rossotti 2015; Sultanik 2015; Carrier 2015) with updated follow up.
Results: Histological, virological and hematological features are summarized in Table 1. Histology distribution was as follows: 12 splenic MZL, 6 extranodal MZL of MALT, 2 leukemic MZL, 2 nodal MZL, 2 CLL/SLL, 1 lymphoplasmacytic lymphoma (LPL) and 1 low grade NHL NOS. Cryoglobulins were present in 13 (symptomatic cryoglobulinemia in 5). HCV genotype was 1 in 15 pts, 2 in 4 pts, 3 in 3 pts and 4 in 2 pts, NA in 2 pts. Three pts previously received chemotherapy and 4 underwent IFN-based therapy before. Twenty-four pts received a SOF-based regimens (SOF + simeprevir in 10, SOF + ribavirin in 5, SOF + daclatasvir in 8, SOF + ledipasvir in 1) and 2 pts other regimens (ombitasvir + paritaprevir + ritonavir + ribavirin and faldaprevir + deleobuvir + ribavirin). In one pt with renal MZL 4 rituximab (R) doses have been added to SOF + simeprevir. Median AT duration was 12 weeks (range: 6-24). At time of present analysis, virological response is available in 21 pts while hematological response has been assessed in 20 pts. A sustained virological response has been obtained in 20 pts; hematological response has been observed only in pts with HCV clearance: in particular 8 pts (all MZL) achieved a complete response and 4 (all MZL) a partial response (comprising one treated also with R) while 5 had stable disease (response by histology is summarized in Table 1). In 7 pts response duration is +1 mo (in 2 pts), +2 mo (in 1 pt), +6 mo (in 3 pts), and +22 mo (in 1 pt); 6 pts (60%) cleared cryoglobulins after AT. After a median follow-up of 6 mo (range: 1-28), 2 pts progressed: one pt shifted to DLBCL and one pt without virological response progressed and died of lymphoma; another pt with hematological CR died of metastatic hepatocellular carcinoma 8 mo after AT. Complete data for all pts will be presented at the meeting.
Conclusions: Our study shows that a significant rate of hematological response can be achieved in HCV-associated MZL also with IFN-free AT. These data are a strong rationale for planning prospective trials with DAA in this setting.
Table 1 - Features of 26 pts with NHL associated with HCV infection treated with IFN-free regimen
and lymphoma response by histology
|
N |
% |
Age, median (range) |
26 |
57 (40-78) |
M/F |
11/15 |
42/58 |
- Marginal-zone lymphoma Splenic Nodal Extranodal of MALT Leukemic MZL - CLL - Lymphoplasmacytic lymphoma - Low-grade B-cell NHL NOS |
22 12 2 6 2 2 1 1 |
84.7 46.2 7.7 23.1 7.7 7.7 3.8 3.8 |
Ann Arbor stage III-IV |
19 |
73 |
B symptoms |
4 |
15 |
ECOG 0 1 2 3 |
11 10 0 1 |
50 45 0 5 |
BM involvement |
14 |
54 |
Extranodal disease |
17 |
65 |
Splenic involvement |
13 |
50 |
Liver involvement |
5 |
19 |
Nodal disease |
15 |
58 |
Bulky disease |
7 |
27 |
Leukemic disease |
9 |
35 |
Elevated LDH |
8/22 |
36 |
Elevated b2-microglobulin |
8/10 |
80 |
Albumin <3.5 g/dl |
3/21 |
14 |
Serum MC |
9/22 |
41 |
HCV genotype - 1 - 2 - 3 - 4 |
15 4 3 2 |
63 17 12 8 |
Cryoglobulins | 13 |
50 |
Symptomatic cryoglobulinemia |
5/13 |
38 |
HBsAg |
1/25 |
4 |
Anti-HBc |
4/25 |
16 |
Lymphoma response by histology - Marginal-zone lymphoma (n=17) Splenic (n=9) Nodal (n=1) Extranodal of MALT (n=5) Leukemic MZL (n=2) - CLL (n=2) - Lymphoplasmacytic lymphoma (n=1) |
CR/PR/SD/Progression 8/4/2/3 4/2/2/1 1/-/-/- 2/1/-/2 1/1/-/- -/-/2/- -/-/1/- |
|
Disclosures: No relevant conflicts of interest to declare.
See more of: Lymphoma: Chemotherapy, excluding Pre-Clinical Models
See more of: Oral and Poster Abstracts
*signifies non-member of ASH